C-mo Medical Solutions raises €4.1 million in seed round
The amount raised by the Portuguese startup will allow it to develop its cough monitoring technology.
Portuguese startup C-mo Medical Solutions has raised €4.1 million in a seed investment round, led by Boehringer Ingelheim Venture Fund and with participation from Portugal Ventures and HighTech Gründerfonds. The amount raised will allow it to bring its cough monitoring technology to market.
“Chronic cough is a highly prevalent symptom, accounting for up to 40% of pulmonologists’ workflow. Cough is a symptom that hides extremely valuable information about the patient’s health, thus bringing enormous clinical value. The European Respiratory Society stated in 2019 that there is an urgent need for appropriate cough monitoring technologies. Developing a solution has been our mission ever since,” explains Diogo Tecelão, co-founder and CEO of C-mo Medical Solutions, in a statement.
The startup’s unique technology analyses the characteristics of the patient’s cough to translate them into knowledge. “It is the first and only solution that can seamlessly monitor the patient’s cough over long periods of time while protecting the patient’s privacy. It is also the first tool that provides a complete and holistic assessment of the patient’s cough characteristics, allowing its application in several key use cases,” he assures.
Diogo Tecelão believes that this is a solution that answers an “urgent” medical need and represents a “powerful” solution to speed up diagnosis, optimise treatment, improve disease management, as well as to support pharmaceutical research.
“We are excited about the new C-mo technology in cough analysis. We think it will provide great value by enabling more specific diagnosis and empowering patients to better understand and manage their disease,” comments Alexander Ehlgen, investment manager at Boehringer Ingelheim Venture Fund.
“This round will enable the company to further develop its product and meet medical needs related to the personalised management of chronic cough and doctor-patient interactions, along with internationalisation to the European and US markets,” says Teresa Fiúza, executive vice president of Portugal Ventures.
